The open-label, randomized, dose optimization Phase 2 international multicenter clinical studies of RC88 in the treatment of gynecological tumors.

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 19 Jan 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs RC 88 (Primary)
Indications Carcinoma; Fallopian tube cancer; Gynaecological cancer; Ovarian cancer; Peritoneal cancer
Focus Adverse reactions; Therapeutic Use

19 Jan 2024 New trial record
28 Dec 2023 According to a RemeGen Co. Ltd media release, company announced that RC88 has recently received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for Phase II clinical trials in the treatment of gynecological tumors. The company is poised to launch international multicenter clinical studies in the United States, China, the European Union, and other regions.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com